Otsuka, Lundbeck Sue Viatris to Block Copies of Abilify Maintena

Otsuka Holdings Co. and H. Lundbeck AS filed two lawsuits in Delaware federal court alleging that Viatris Inc.’s proposed generic version of Abilify Maintena infringes eight patents for the monthly injectable treatment for schizophrenia that Lundbeck exclusively licenses from Otsuka.

Otsuka and Lundbeck filed the complaints against Viatris, formerly known as Mylan, April 8 in the U.S. District Courts for the District of Delaware and for the Northern District of West Virginia.

Viatris is incorporated in Delaware. Mylan Pharmaceuticals Inc., a co-defendant in both cases, is incorporated in Morgantown, W.Va.

Abilify Maintena, which also is used ...